Praxis Precision Medicines, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Praxis is a clinical-stage biopharmaceutical company developing CNS therapies through its Cerebrum small-molecule and Solidus antisense oligonucleotide platforms. It reported no product sales; its only reported revenue was collaboration revenue.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Collaboration revenue | $0.7 million | None |
| Research and development expense | $25.5 million | $52.7 million |
| General and administrative expense | $13.3 million | $16.2 million |
| Net loss | $37.5 million | $68.7 million |
| Net loss per share, basic and diluted | $0.71 | $1.51 |
| Net cash used in operating activities | $32.8 million | $54.1 million |
- At March 31, cash and cash equivalents were $80.8 million and marketable securities were $5.0 million, totaling $85.8 million. Current assets were $94.4 million and current liabilities were $29.9 million.
- Cash increased by $19.2 million during the quarter: $34.0 million from marketable-security maturities and $18.1 million of net financing proceeds partly offset $32.8 million of operating cash use.
- Total liabilities were $33.9 million, including lease liabilities and deferred revenue; the balance sheet reported no borrowings. No gross margin was reported.
- Stockholders’ equity was $64.5 million. Shares outstanding rose from 49.4 million at year-end to 58.0 million at March 31, reflecting, in part, issuance of 8.4 million shares through the at-the-market program for $18.1 million net proceeds. The filing reported 62.1 million shares outstanding on May 5.
Material changes versus Q1 2022
- Net loss narrowed by $31.3 million, while operating expenses declined by $30.1 million.
- R&D expense fell by $27.1 million, chiefly from lower Cerebrum spending, including reduced PRAX-114 costs following the 2022 strategic realignment, and lower PRAX-562 and earlier-stage program costs. Lower Solidus and personnel costs also contributed. These decreases were partly offset by higher indirect R&D expense and PRAX-628 clinical spending.
- G&A expense declined by $2.9 million, primarily due to lower consulting and other costs. Other income increased to $0.6 million, mainly reflecting interest income.
- The company recognized $0.7 million of UCB collaboration revenue in Q1 2023 as it performed research services; $4.3 million remained deferred at quarter-end.
Outlook, risks and contingencies
- Funding and going concern: Management estimated that March 31 cash, cash equivalents and marketable securities would fund operations into Q2 2024 under its current plan, which limits advancement to candidates’ current clinical phases. The company also stated that these resources may not cover at least 12 months from issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern. It expects ongoing losses and needs additional funding; no committed external funding source was identified.
- Pipeline plans: An FDA end-of-Phase 2 meeting for ulixacaltamide (PRAX-944) was scheduled for June 2023, with a Phase 3 essential tremor study intended for the second half of 2023. Praxis expected PRAX-562 EMBOLD topline results in Q4 2023, PRAX-628 Phase 2 initiation in focal epilepsy in Q4 2023, and first-cohort PRAX-222 EMBRAVE topline results in the second half of 2023. The filing also reports that PRAX-628 Phase 1 results were positive in May 2023, after quarter-end. These are expectations, not assured outcomes.
- UCB agreement: The December 2022 agreement provides a $5.0 million upfront payment for research services and potential option, milestone payments totaling up to $98.5 million, and tiered royalties if applicable. Future payments depend on specified events and are not assured.
- Principal risks: Clinical and regulatory uncertainty, trial delays or failures, manufacturing and third-party execution, intellectual-property protection, competition and the ability to obtain financing. The company cautioned that early or open-label results may not predict later trial outcomes; regulatory acceptance of novel endpoints may also be uncertain.
- No material legal proceedings or material subsequent events requiring disclosure were reported. Management concluded disclosure controls were effective as of March 31, 2023.
Key facts for investors to verify
- Whether Praxis raises additional capital, on what terms, and whether financing resolves the disclosed going-concern uncertainty.
- Actual cash use and clinical spending versus the plan supporting the stated runway into Q2 2024.
- FDA feedback and execution of the planned ulixacaltamide Phase 3 program, including endpoint and trial-design requirements.
- Timing and results for PRAX-562, PRAX-628 and PRAX-222, and any effects on spending or development priorities.
- Further dilution from equity issuance and the conditional nature of UCB option, milestone and royalty potential.